Roivant's Lung Disease Drug Achieves Mid-Stage Study Goals
Source Summary
Roivant Sciences announced positive results from a mid-stage clinical trial of its lung disease drug. The drug met its study goals, potentially establishing a new treatment approach for serious lung conditions.
Why it matters
Positive mid-stage results advance the drug toward potential regulatory approval and could provide patients with a new treatment option for serious lung disease.
